Resultados de la búsqueda 331-340 of 4269 for Relapse

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Ensayos clínicos · A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia ( ...

  2. Oncología (médica) - Ensayos clínicos

    Patients at high risk of relapse are eligible for InPACT-pelvis, where they ... Also, to improve disease control by decreasing the number of spinal relapses ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or ...

  5. Oncología (médica) - Ensayos clínicos

    A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small ...

  6. Oncología (médica) - Ensayos clínicos

    A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small ...

  7. Hematología - Ensayos clínicos

    The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, (RR ...

  8. Oncología (médica) - Ensayos clínicos

    This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...

  9. Oncología (médica) - Ensayos clínicos

    This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...